Emergent BioSolutions
EBS
$2.86
Share price
-4.28%
Change (1 day)
-90.68%
Change (1 year)
Categories
Emergent BioSolutions (EBS) - Net assets
Net assets on the balance sheet as of June 2023 : $0.95 B
According to Emergent BioSolutions
's latest financial reports the company has $0.95 B in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Emergent BioSolutions - Net assets on balance sheet (from 2004 to 2023)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2022-12-31 | $1.38 B | -14.58% |
| 2021-12-31 | $1.61 B | 11.89% |
| 2020-12-31 | $1.44 B | 32.94% |
| 2019-12-31 | $1.08 B | 7.68% |
| 2018-12-31 | $1.01 B | 10.8% |
| 2017-12-31 | $0.91 B | 53.03% |
| 2016-12-31 | $0.59 B | -9.67% |
| 2015-12-31 | $0.66 B | 19.31% |
| 2014-12-31 | $0.55 B | 13.09% |
| 2013-12-31 | $0.48 B | 10.64% |
| 2012-12-31 | $0.44 B | 6.1% |
| 2011-12-31 | $0.41 B | 11.56% |
| 2010-12-31 | $0.37 B | 53.21% |
| 2009-12-31 | $0.24 B | 22.31% |
| 2008-12-31 | $0.19 B | 16.47% |
| 2007-12-31 | $0.17 B | 23.61% |
| 2006-12-31 | $0.13 B | 131.8% |
| 2005-12-31 | $59.73 M | 160.3% |
| 2004-12-31 | $22.94 M | |
| 2002-12-31 | $4.15 M | -112.87% |
| 2001-12-31 | $-32.3 M |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $99.29 B | 10,283.04% | 🇺🇸 USA |
 Merck MRK | $38.74 B | 3,951.24% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $15.33 B | 1,503.90% | 🇬🇧 UK |
 Soligenix SNGX | $5.8 M | -99.39% | 🇺🇸 USA |
 SIGA Technologies SIGA | $0.12 B | -87.03% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $0.27 B | -70.98% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $7.70 B | 706.02% | 🇮🇱 Israel |